In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

A safety net health care provider has won a $10.3 million interim arbitration judgment against Eagan-based Prime Therapeutics over price-fixing allegations between the local pharmacy benefits manager ...

Bloomfield-based Cigna announced this week a new initiative that aims to reduce out-of-pocket prescription-drug costs and ...

Fresh off underperforming Wall Street’s expectations in the fourth quarter, Cigna said it would work to lower costs for its ...

Cigna executives kicked off Thursday’s earnings call by responding to pharmacy benefit manager critics with a number of reforms.

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

The National Community Pharmacists Association has joined a class action lawsuit against GoodRx, as well as CVS Caremark, ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...